Objective Juvenile SLE (jSLE) is an autoimmune disease characterised by the presence of high levels of autoantibodies, ...

Objective Both belimumab and telitacicept are recognised blockers for B lymphocyte activation, both of which have been ...

Objective Epstein–Barr virus (EBV) has for long been associated with systemic lupus erythematosus (SLE). In this study, we investigated the levels of latent and lytic antigen EBV-specific T-cells and ...

Objectives Evaluation of disease activity in systemic lupus erythematosus (SLE) nephritis is a challenge, and repeated renal biopsies are usually needed in order to confirm a suspicion of flare. In a ...

Original research: Racial differences in clinical trial perceptions among a large, predominantly Black cohort of people with systemic lupus erythematosus in the Southeastern USA (4 January, 2025) ...

1 Center of Expertise for Lupus, Vasculitis and Complement-mediated Systemic disease (LuVaCs), Dept. of Nephrology, Leiden University Medical Center, Leiden, The Netherlands 2 Dept. of Nephrology, ...

1 Dept. of Rheumatology and Clinical Immunology, Amsterdam Rheumatology and immunology Center, Amsterdam institute for Infection and Immunity, Amsterdam University Medical Center, Amsterdam, The ...

1 Dept. of Clinical Neuroscience, Karolinska Institutet, Karolinska University Hospital, Solna, Stockholm, Sweden 2 Dept. of Neuroradiology, Karolinska University ...

Objective We performed a scoping review of randomised clinical trials (RCTs) assessing pharmacological therapies for the initial management of lupus nephritis (LN), focusing on study design, included ...

Objectives Antiphospholipid syndrome (APS) is characterised by the presence of antiphospholipid antibodies (aPLs) and clinical outcomes of thrombosis and/or obstetric ...